Author:
Yue Ting,Zheng Xiaodong,Dou Yaling,Zheng Xiaohu,Sun Rui,Tian Zhigang,Wei Haiming
Funder
National Natural Science Foundation of China (CN)
National Basic Research Project
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference55 articles.
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi: 10.3322/caac.20107 .
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. doi: 10.3322/caac.21166 .
3. Dimitroulis J, Rapti A, Stathopoulos GP, Rigatos S, Stathopoulos J, Koutantos J, et al. Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposide in patients with small-cell lung cancer: a Phase III study. Oncol Rep. 2008;20(4):879–84.
4. Gupta N, Hatoum H, Dy GK. First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel. Int J Nanomedicine. 2014;9:209–21. doi: 10.2147/IJN.S41770 .
5. Rossi A, Chiodini P, Sun JM, O’Brien ME, von Plessen C, Barata F, et al. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2014;15(11):1254–62. doi: 10.1016/S1470-2045(14)70402-4 .
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献